Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Receivables (2016 - 2026)

Angiodynamics' Receivables history spans 16 years, with the latest figure at $45.6 million for Q1 2026.

  • For Q1 2026, Receivables rose 4.79% year-over-year to $45.6 million; the TTM value through Feb 2026 reached $45.6 million, up 4.79%, while the annual FY2025 figure was $42.9 million, 1.65% down from the prior year.
  • Receivables reached $45.6 million in Q1 2026 per ANGO's latest filing, up from $44.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $53.6 million in Q3 2022 to a low of $39.6 million in Q3 2024.
  • Average Receivables over 5 years is $47.1 million, with a median of $45.6 million recorded in 2026.
  • Peak YoY movement for Receivables: skyrocketed 51.3% in 2022, then dropped 20.48% in 2024.
  • A 5-year view of Receivables shows it stood at $52.9 million in 2022, then fell by 2.36% to $51.6 million in 2023, then decreased by 16.37% to $43.2 million in 2024, then grew by 2.96% to $44.4 million in 2025, then rose by 2.52% to $45.6 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Receivables are $45.6 million (Q1 2026), $44.4 million (Q4 2025), and $42.6 million (Q3 2025).